AN Venture Partners
Overview
AN Venture Partners is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Crystalys Therapeutics | Jul 2026 | Series B | Co-investor |
| Imbria Pharmaceuticals | Apr 2025 | Series B | Co-investor |
| Tortugas Neuroscience | Aug 2026 | Series A | Lead |
| Pahr Therapeutics | Jul 2025 | Seed | Lead |
| City Therapeutics | Jun 2026 | Series B | Co-investor |
For institutional investors. Book with your work email.
Key People
Ken Horne
Managing Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is AN Venture Partners based?
AN Venture Partners is headquartered in San Francisco, California, United States.
When was AN Venture Partners founded?
AN Venture Partners was founded in 2022.
How many portfolio companies does AN Venture Partners have?
AN Venture Partners has 7 portfolio companies in Caplight's dataset.
What are some companies in AN Venture Partners's portfolio?
Portfolio companies visible on Caplight include Crystalys Therapeutics, Imbria Pharmaceuticals, Tortugas Neuroscience, Pahr Therapeutics, City Therapeutics.
What was AN Venture Partners's most recent investment shown here?
AN Venture Partners's most recent investment in this portfolio sample was in Tortugas Neuroscience in 2026.
What sectors does AN Venture Partners focus on?
AN Venture Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does AN Venture Partners focus on?
AN Venture Partners typically invests at the Early stage.
What is AN Venture Partners's AUM?
AN Venture Partners's assets under management are estimated between $200.0M and $200.0M.